Urine analysis enables cardiovascular risk assessment
Coronary artery disease (CAD) is the leading cause of morbidity and mortality worldwide. A vast amount of deaths and disabilities caused by CAD could be cut by an early diagnosis, enabling effective individual actions for preventing clinical events like acute myocardial infarction.
Researchers of mosaiques diagnostics, the British Heart Foundation (Glasgow, UK), and Baker Heart Research Institute (Melbourne, Australia) examined a total of 370 patients in an international blinded clinical study. The consortium established a diagnostic urine test distinguishing between presence and absence of CAD with sensitivity of 98% and specificity of 83%. Mosaiques' proprietary CE-MS technology (capillary electrophoresis coupled to mass spectrometry) enabled not only the successful identification of CAD patients, but also suggests the possibility of monitoring the effects of therapeutic interventions. This non invasive and precise diagnostic procedure provides tremendous benefits for patients with significantly increased risk of cardiovascular complications, such as patients with type II diabetes and the elderly in personalized medicine. According to the company, the technology already proved high advancement and impact on drug evaluation during clinical trials by a detailed assessment of drug effects on the vascular and - considering mosaiques' further diagnostics - renal architecture.
Original publication: "Urinary proteomic biomarkers in coronary artery disease."; Molecular & Cellular Proteomics 2007.
Topics
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
See the theme worlds for related content
Topic World Mass Spectrometry
Mass spectrometry enables us to detect and identify molecules and reveal their structure. Whether in chemistry, biochemistry or forensics - mass spectrometry opens up unexpected insights into the composition of our world. Immerse yourself in the fascinating world of mass spectrometry!

Topic World Mass Spectrometry
Mass spectrometry enables us to detect and identify molecules and reveal their structure. Whether in chemistry, biochemistry or forensics - mass spectrometry opens up unexpected insights into the composition of our world. Immerse yourself in the fascinating world of mass spectrometry!
Last viewed contents

Flexible organic electronics mimic biological mechanosensory nerves
PAREXEL Forms Collaboration With Clinical Research Services Provider in India
Benitec secures further rights to HIV Therapeutic - Collaboration with City of Hope in HIV trial
William Vickery joins Hybrigenics as Head of Corporate and Business Development

Expansion Sees Q Chip Move to New Facility
MDxHealth's ConfirmMDx Genes Detect Clinically Significant Prostate Cancer
Millipore Acquires NovAseptic AB: Broadens Offering to Biotech and Pharmaceutical Industry
Evotec and Celgene collaborate in drug discovery for neurogenerative diseases
Evotec and Roche Form Global Alliance to Jointly Discover Novel Drugs
